(Q54457707)
Statements
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (English)
Tadeusz Pienkowski
Istvan Lang
Thomas Brodowicz
Larisa Ryvo
Zsuzsanna Kahan
Richard Greil
Semir Beslija
Salomon M Stemmer
Bella Kaufman
Zanete Zvirbule
Günther G Steger
Bohuslav Melichar
Daniela Sirbu
Diethelm Messinger
Christoph Zielinski
Central European Cooperative Oncology Group
10 January 2013
14
2
125-133